Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CRBP – Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings
CRBP
$8.14
Name : Corbus Pharmaceuticals Holdings
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $142,881,712.00
EPSttm : -5.49
finviz dynamic chart for CRBP
Corbus Pharmaceuticals Holdings
$8.14
1.62%
$0.13

Float Short %

8

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

0.44

EPS Last/This Y

-3.02

EPS This/Next Y

1.49

Price

8.12

Target Price

42.05

Analyst Recom

1

Performance Q

-37.58

Relative Volume

0.4

Beta

2.75

Ticker: CRBP




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02CRBP10.280.450.174433
2025-12-03CRBP10.690.460.024376
2025-12-04CRBP10.660.450.004410
2025-12-05CRBP10.240.450.004397
2025-12-08CRBP10.370.460.094368
2025-12-09CRBP10.090.460.124372
2025-12-10CRBP10.460.463.334367
2025-12-11CRBP9.650.460.214375
2025-12-12CRBP9.690.420.005383
2025-12-15CRBP9.470.390.215718
2025-12-16CRBP8.650.380.085681
2025-12-17CRBP8.150.380.605713
2025-12-18CRBP8.110.250.285185
2025-12-19CRBP8.10.250.135198
2025-12-22CRBP8.330.120.001650
2025-12-23CRBP8.180.100.021949
2025-12-26CRBP8.320.092.001988
2025-12-29CRBP8.230.092.141975
2025-12-30CRBP8.050.100.002013
2025-12-31CRBP8.130.090.001989
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02CRBP10.28-104.5-25.6-6.71
2025-12-03CRBP10.67-104.5-43.5-6.71
2025-12-04CRBP10.65-104.5-34.7-6.71
2025-12-05CRBP10.24-104.5-25.6-6.71
2025-12-08CRBP10.37-104.5- -6.71
2025-12-09CRBP10.10-104.5-29.8-6.71
2025-12-10CRBP10.10-104.5-40.0-6.71
2025-12-11CRBP9.68-104.5-22.9-6.71
2025-12-12CRBP9.67-104.5-34.4-6.71
2025-12-15CRBP9.48-104.5-29.8-6.71
2025-12-16CRBP9.48-104.5-12.0-6.71
2025-12-17CRBP8.13-104.5-17.5-6.71
2025-12-18CRBP8.11-104.5-34.3-6.71
2025-12-19CRBP8.10-104.5-36.1-6.71
2025-12-22CRBP8.40-104.5-49.4-6.71
2025-12-23CRBP8.19-104.5-29.6-6.71
2025-12-26CRBP8.31-104.5-30.1-6.71
2025-12-29CRBP8.20-104.5-31.0-6.71
2025-12-30CRBP8.02-104.5-26.9-6.71
2025-12-31CRBP8.12-104.5-40.8-6.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02CRBP-3.24-1.575.95
2025-12-03CRBP-2.96-1.575.95
2025-12-04CRBP-2.96-1.575.95
2025-12-05CRBP-2.96-1.575.95
2025-12-08CRBP-2.96-1.175.95
2025-12-09CRBP-2.96-1.175.95
2025-12-10CRBP-2.96-1.176.29
2025-12-11CRBP-2.96-1.176.29
2025-12-12CRBP-2.96-1.176.29
2025-12-15CRBP-4.98-1.186.32
2025-12-16CRBP-4.73-1.186.32
2025-12-17CRBP-4.73-1.186.32
2025-12-18CRBP-4.73-1.186.32
2025-12-19CRBP-4.73-1.186.32
2025-12-22CRBP-4.73-1.186.32
2025-12-23CRBP-4.73-1.186.32
2025-12-26CRBP-4.73-1.188.00
2025-12-29CRBP-4.73-1.188.00
2025-12-30CRBP-4.73-1.188.00
2025-12-31CRBP-4.73-1.188.00
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.9

Avg. EPS Est. Current Quarter

-1.59

Avg. EPS Est. Next Quarter

-1.46

Insider Transactions

-4.73

Institutional Transactions

-1.18

Beta

2.75

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

22

Sentiment Score

75

Actual DrawDown %

93.2

Max Drawdown 5-Year %

-97.9

Target Price

42.05

P/E

Forward P/E

PEG

P/S

P/B

1.11

P/Free Cash Flow

EPS

-5.51

Average EPS Est. Cur. Y​

-6.71

EPS Next Y. (Est.)

-5.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.4

Return on Equity vs Sector %

-100.6

Return on Equity vs Industry %

-85.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.32

EBIT Estimation

-40.8
Corbus Pharmaceuticals Holdings
Sector: Healthcare
Industry: Biotechnology
Employees: 28
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
stock quote shares CRBP – Corbus Pharmaceuticals Holdings, Inc. Stock Price stock today
news today CRBP – Corbus Pharmaceuticals Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRBP – Corbus Pharmaceuticals Holdings, Inc. yahoo finance google finance
stock history CRBP – Corbus Pharmaceuticals Holdings, Inc. invest stock market
stock prices CRBP premarket after hours
ticker CRBP fair value insiders trading